M. Seke

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · The Lancet · 2019 · 871 citations

Medicine, Radiation Oncology, Urology +16

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson et al. · The Lancet Oncology · 2021 · 157 citations

Medicine, Oncology, Radiation Oncology +17

Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”

Anders Widmark, Adalsteinn Gunnlaugsson, L. Beckman et al. · International Journal of Radiation Oncology*Biology*Physics · 2016 · 37 citations

Medicine, Oncology, Radiation Oncology +14

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

P-L Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg‐Karlsson et al. · Prostate Cancer and Prostatic Diseases · 2012 · 27 citations

Medicine, Oncology, Radiation Oncology +17